The MuLBSTA score—which incorporates multilobe infiltrate, absolute lymphocyte count ≤0.8 x 109/L, bacterial coinfection, smoking history, history of hypertension and age ≥60 years—was recently developed in China to predict 90-day mortality in patients with viral pneumonia. With the score taking into account some of the factors that make COVID-19 unique, US researchers explored the applicability of MuLBSTA scores in predicting disease severity and mortality risk in patients with COVID-19. When applied to each patient at time of hospitalization, MuLBSTA had mean scores of 8.67 for patients who survived and 13.6 for those who died. A significant positive correlation of MuLBSTA score with mortality (odds ratio p[OR], 1.37) was observed. A positive correlation was also seen with need for ventilator support (OR, 1.30) and length of stay. The area under the receiver operatic characteristic curve of MuLBSTA for predicting in-hospital mortality at time of admission was 0.813. The study authors suggest MuLBSTA score could help direct treatment type in this patient population.
- ACC 2020The American College of Cardiology decided to cancel ACC.20/WCC due to COVID-19, which was scheduled to take place March 28-30 in Chicago. However, ACC.20/WCC Virtual Meeting continues to release cutting edge science and practice changing updates for cardiovascular professionals on demand and free through June 2020.
- ENDO: 2020ENDO 2020 Annual Conference has been canceled due to COVID-19. Here are highlights of emerging data that has still been released. Keep an eye out for ENDO Online 2020, which will take place from June 8 to 22.
- CROI 2020Every year, CROI hosts some of the world's leading experts in HIV research, who come to present exciting new data and drive forward the field of HIV/AIDS research. This year, due to COVID-19, CROI held their meeting virtually.